US 12,344,663 B2
Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
Leonardo Borras, Birmensdorf (CH); Pankaj Gupta, Scarsdale, NY (US); Stephanie Jungmichel, Oerlikon-Zuerich (CH); Christian Leisner, Thalwil (CH); Philipp Robert Richle, Zurich (CH); Fabian Scheifele, Maegenwil-Aargau (CH); and Anna Sobieraj, Schlieren (CH)
Assigned to CDR-Life AG, Schlieren (CH); and Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by CDR-Life AG, Schlieren (CH); and Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Dec. 21, 2022, as Appl. No. 18/069,712.
Claims priority of provisional application 63/292,513, filed on Dec. 22, 2021.
Prior Publication US 2023/0257455 A1, Aug. 17, 2023
Int. Cl. C07K 16/18 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [G01N 33/6893 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2333/4716 (2013.01)] 94 Claims
 
1. A monoclonal anti-C3 antibody or an antigen-binding fragment thereof comprising a heavy chain variable region (VH), and a light chain variable region (VL),
wherein the VH comprises the CDR-H1 sequence of SEQ ID NO: 1, the CDR-H2 sequence of SEQ ID NO: 2 or 15, and the CDR-H3 sequence of SEQ ID NO: 3; and
wherein the VL comprises the CDR-L1 sequence of SEQ ID NO: 4, the CDR-L2 sequence of SEQ ID NO: 5 or 18, and the CDR-L3 sequence of SEQ ID NO: 6.